《大行報告》摩通下調港交所(00388.HK)目標價至388元 評級「增持」
摩根大通發表報告指,將港交所(00388.HK)列入正面催化劑觀察名單,主要是預料在6月19日推出港幣-人民幣雙櫃台模式的一星期過後,即6月26日,料大市將會迎來更佳的成交表現。
該行表示,港交所推出雙櫃台模式能扭轉近期成交量疲軟的契機,同時推動中國與世界互聯互通繼續擴大的長期趨勢。該行指,將港交所在2023年至2025年的每股盈測下調2%至7%,並將其目標價由400元下調至388元,維持其評級為「增持」。(ca/w)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.